


B



BEST AVAILABLE COPY

**FAX TRANSMISSION****DATE:** July 1, 2005**PTO IDENTIFIER:** Application Number 10/040281-Conf. #9658  
Patent Number**Inventor:** Jeffrey L. BROWNING et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (703) 746-4000**FROM:** LAHIVE & COCKFIELD, LLP

Cristin E. Howley, Ph.D.

**PHONE:** (617) 227-7400**Attorney Dkt. #:** BGNB129CP2DV2CN**PAGES (Including Cover Sheet):** 31**CONTENTS:** Transmittal (1 page)  
Communication (2 pages)  
Copy of Information Disclosure Statement filed July 2, 2002 (26 pages)  
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

**LAHIVE & COCKFIELD, LLP**  
28 State Street, Boston, Massachusetts 02109  
Telephone: (617) 227-7400 Facsimile: (617) 742-4214




PTO/SB/21 (09-04)  
 Approved for use through 07/31/2008. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/040281-Conf. #9658
	Filing Date	November 7, 2001
	First Named Inventor	Jeffrey L. BROWNING
	Art Unit	1635
	Examiner Name	S. McGarry
Total Number of Pages In This Submission	Attorney Docket Number	BGNB129CP2DV2CN

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Communication - Copy of Information Disclosure Statement mailed 7/2/02 - Fax Cover Sheet - Certificate of Fax Transmission
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Cristin E. Howley, Ph.D.		
Date	July 1, 2005	Reg. No.	55,281

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 748-4000 at MS Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: July 1, 2005	Signature:  (Cristin E. Howley, Ph.D.)



07/01/2005 18:10 FAX 8177424214

LAHIVE&COCKFIELD

003/031

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 748-4000 at MS Issue Fee Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 1, 2005

Signature:

(Cristin E. Rowley)

Docket No.: BGNB129CP2DV2CN  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Jeffrey L. Browning *et al.*

Application No.: 10/040281

Confirmation No.: 9658

Filed: November 7, 2001

Art Unit: 1635

For: *Lymphotoxin-B, Lymphotoxin-B Complexes,  
Pharmaceutical Preparations And Therapeutic  
Uses Thereof*

Examiner: S. McGarry

MS Issue Fee  
P.O. Box 1450  
Alexandria, VA 22313-1450

**COMMUNICATION**

Dear Sir:

Upon receipt of the Notice of Allowance, the file for the above-referenced case was reviewed and it was noted that a copy of PTO Form 1449 initialed by the Examiner had not been received. In a conversation with the Examiner, Applicants' agent was informed that the Patent Office had not received the Information Disclosure Statement dated July 2, 2002.

Enclosed please find a copy of the Information Disclosure Statement mailed July 2, 2002 to the Patent Office, including a copy of the Information Disclosure Statement, Transmittal Form, PTO Form 1449 (including Forms PTO/SB/08A and PTO/SB/08B), Supplemental Communication, International Search Report from a counterpart foreign application, Certificate of Mailing, and Return Postcard.

Application No.: 10/040281

Docket No.: BGNB129CP2DV2CN

Applicants respectfully request entry of these documents and consideration by the Examiner. Following consideration, Applicants request that the Examiner forward to Applicants' attorney an initialed copy of PTO Form 1449.

Dated: July 1, 2005

Respectfully submitted,

By 

Cristin E. Howley

Registration No.: 55,281

LAHIVE &amp; COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Agent For Applicant

BEST AVAILABLE COPY



Title: Lymphotoxin-Beta, Lymphotoxin-Beta Complexes, Pharmaceutical Preparations And Therapeutic Uses Thereof  
 Serial No. 10/040281 Applicant: Browning et al.


In the above matter, the following have been received by the US Patent and Trademark Office on the date stamped hereon.

- |  |  |
|--|--|
| <ul style="list-style-type: none"> <li><input type="checkbox"/> Express Mail Label No. _____</li> <li><input type="checkbox"/> Application incl. _____ pages</li> <li>_____ pp. of specification</li> <li>_____ pp. of claims (# of claims- _____)</li> <li>_____ pp. of abstract</li> <li>_____ sheets of drawings; Figs. _____</li> <li><input type="checkbox"/> Provisional Application Cover Sheet</li> <li><input type="checkbox"/> Declaration/Power of Attorney (____ Unsigned)</li> <li><input type="checkbox"/> Copy of Notice to File Missing Parts</li> <li><input type="checkbox"/> Request for filing RCE</li> <li><input checked="" type="checkbox"/> IDS, PTO-1449 and _____ references (Supp. _____)</li> <li><input checked="" type="checkbox"/> Other: IDS - Supplemental Communication</li> <li><input checked="" type="checkbox"/> Other: Copy of Int'l Search Report</li> </ul> | <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Certificate of Mailing under 37 CFR</li> <li><input type="checkbox"/> Response to Office Action/Restriction</li> <li><input type="checkbox"/> Petition for _____ month extension of time</li> <li><input type="checkbox"/> Assignment and Cover Sheet</li> <li><input type="checkbox"/> Amendment (____ Preliminary ____ After Final)</li> <li><input type="checkbox"/> Notice of Appeal</li> <li><input type="checkbox"/> Appellant's Brief(triplicats)(____ Reply Brief)</li> <li><input type="checkbox"/> Letter to Chief Draftsperson</li> <li><input type="checkbox"/> Issue Fee</li> <li><input checked="" type="checkbox"/> Transmittal Letter</li> <li><input checked="" type="checkbox"/> Deposit Account Authorization \$ <u>02-2327</u></li> </ul> |
|--|--|
- Mailing Date: July 2, 2002 Docket No. B129CIP2DIV2CON Atty/asst: NDC/jlm



PATENT ADMINISTRATOR  
 BIOGEN, INC.  
 14 CAMBRIDGE CENTER  
 CAMBRIDGE, MA 02142

BEST AVAILABLE COPY



PTO/SB/82 (12-97)  
Approved for use through 8/30/00. OMB 0851-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**COPY**

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

on July 2, 2002  
Date

Signature


Jacqueline L. Marlier

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

1. PTO Form 1449 (8 pgs.)
2. Information Disclosure Statement Transmittal Form (3 pgs.);
3. General Transmittal Form (1 pg.);
4. IDS - Supplemental Communication (1 pg.);
5. Copy of International Search Report from a counterpart foreign application (8 pgs.);
5. Return Receipt Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒Approved for use through 09/30/2000, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/040,281	
	Filing Date	11/07/2001	
	First Named Inventor	Browning, Jeffrey	
	Group Art Unit	1635	
	Examiner Name	TBD	
Total Number of Pages in This Submission	22	Attorney Docket Number	B129USCP2DV2CO

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavit/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/68) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) PTO Form 1449 IDS - Supplemental Communication Copy of Int'l Search Report
Remarks The Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 02-2327		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Niki D. Cox, Esq.	Reg. No. 42,446
Signature	<i>Niki D. Cox</i>	
Date	July 2, 2002	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: July 2, 2002

Typed or printed name	Jacqueline L. Marlier
Signature	<i>Jacqueline L. Marlier</i>
Date	July 2, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Docket No.: B129 CIP2DIV2CON

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Examiner: TBD

Browning et al.

Group Art Unit: 1635

Serial No.: 10/040,281

Filing Date: November 7, 2001

For: LYMPHOTOXIN- $\beta$ , LYMPHOTOXIN- $\beta$  COMPLEXES,  
PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES  
THEREOF

## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on:

July 2, 2002  
Date

Jacqueline L. Marlier  
Jacqueline L. Marlier

## SUPPLEMENTAL COMMUNICATION

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The attached Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits and therefore no fee is due. In an abundance of caution, however, the Assistant Commissioner is hereby authorized to charge Deposit Account No. 02-2327 for any unforeseen fee that may be due.

If the Examiner believes that consideration of the application, or of any matter related to this submission, would be facilitated by a telephone conference with


#10788



Applicants' attorney, the Examiner is urged to contact the undersigned at the telephone number set forth below.

Date: July 2, 2002

Respectfully submitted,



Niki D. Cox, Esq.  
Reg. No. 42,446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079 (Direct)  
(617) 679-2838 (Facsimile)

#10788



Docket No.: B129 CIP2DIV2CON

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Examiner: TBD

Browning et al.

Group Art Unit: 1635

Serial No.: 10/040,281

Filing Date: November 7, 2001

For: LYMPHOTOXIN- $\beta$ , LYMPHOTOXIN- $\beta$  COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF

## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on:

July 2, 2002  
Date  
Jacqueline L. MarlierINFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:☐ a Statement under 37 CFR 1.97(e), as checked below, or☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:☐ a Statement under 37 CFR 1.97(e), as checked below, and☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

-2-

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are not enclosed; said references were cited in prior application, U.S. Application No. 07/990,304, to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☒ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.

-3-

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

Examiner

Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 02-2327 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 02-2327.

Respectfully submitted,

BIOGEN, INC.

Date:

July 2, 2002

  
Niki D. Cox, Esq.

Reg. No. 42,446

BIOGEN, INC.

14 Cambridge Center

Cambridge, MA 02142

(617) 679-2079 (Direct)

(617) 679-2838 (Facsimile)

10789



→  $\sqrt{\quad}$

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/040,281
				Filing Date	11/07/2001
				First Named Inventor	Browning, Jeffrey
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	1	of	8	Attorney Docket Number	B129USCP2DV2CO


[illegible][illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box → ☐ +

Approved for use through 10/1/99, PTO/SB/08B (10-86)  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/040,281
				Filing Date	11/07/2001
				First Named Inventor	Browning, Jeffrey
				Group Art Unit	TBD
				Examiner Name	TBD
				Attorney Docket Number	B129USCP2DV2CO
Sheet	2	of	8		


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Y. Abe et al., "Expression of Membrane-Associated Lymphotoxin/Tumor Necrosis Factor-Beta on Human Lymphokine Killer Cells", Jpn. J. Canc. Res., 82, pp. 23-26, (1991).	
	C2	Y. Abe et al., "Studies of Membrane-Associated and Soluble (Secreted) Lymphotoxin in Human Lymphokine-Activated T-Killer Cells in Vitro", Lymphokine and Cytokine Research, Vol. 11, pp. 115-121, (1992).	
	C3	Abersold et al., "Internal Amino Acid Sequence Analysis of Proteins Separated by One- or Two-Dimensional Gel Electrophoresis After in situ Protease Digestion on Nitrocellulose", PNAS, Vol. 84, pp. 6970-6974, (1987).	
	C4	B. Aggarwal et al., "Primary Structure of Human Lymphotoxin Derived from 1788 Lymphoblastoid Cell Line", J. Biol. Chem., Vol. 260, No. 4, pp. 2334-2344, (1985).	
	C5	M. Akashi et al., "Lymphotoxin: Stimulation and Regulation of Colony-Stimulating Factors in Fibroblasts", Blood, 74, No. 7, pp. 2383-2390, (1989).	
	C6	W.F. Anderson, "Human Gene Therapy", Science, Vol. 256, pp. 808-813 (1992).	
	C7	U. Anderson et al., "Characterization of Individual Tumor Necrosis Factor alpha- and beta-Producing Cells after Polyclonal T Cell Activation", J. of Immun. Meth., 123, pp. 233-240, (1989).	
	C8	J.S. Andrews et al., Characterization of the Receptor for Tumor Necrosis Factor (TNF) and Lymphotoxin (LT) on Human T Lymphocytes", J. Immun., Vol. 144, No. 7, pp. 2528-2591, (1990).	
	C9	Androlewicz et al., "Lymphotoxin is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma", Journal of Biological Chemistry, 267, No. 4, pp. 2542-2547, (1992).	
	C10	R. Armitage et al., "Molecular and Biological Characterization of a Murine Ligand for CD40", Nature, Vol. 357, pp. 80-82, (1992).	
	C11	K. Badenhop et al., "TNF-alpha Gene Polymorphisms in Type 1 (Insulin-Dependent) Diabetes Mellitus", Diabetologia, 32, 445-448, (1989).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/55/08B (10-98)

Approved for use through 10/31/99, OMB 0551-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

8

**Complete If Known**

Application Number	10/040,281
Filing Date	11/07/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	B129USCP2DV2CO

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C12	B. Beutler et al., "The History, Properties, and Biological Effects of Cachectin", Biochemistry, Vol. 27, No. 20, pp. 7575-7582, (1988).	
	C13	T. Bringman et al., "Monoclonal Antibodies to Human Tumor Necrosis Factors alpha and beta: Application for Affinity Purification, Immunoassays, and as Structural Probes", Hybridoma, 6, No. 5, pp. 489-507, (1987).	
	C14	J. Browning et al., "Studies on the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines", J. Immun., Vol. 143, No. 6, pp. 1859-1867, (1989).	
	C15	J. Browning et al., "Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma", J. Immunol., Vol. 147, No. 4, pp. 1230-1237, (1991).	
	C16	D. Cavender et al., "Endothelial Cell Activation Induced by Tumor Necrosis Factor and Lymphotoxin", Amer. J. Path., Vol. 134, No. 3, pp. 551-560, (1989).	
	C17	R. Couran et al., "Endothelial Activation, its Role in Inflammatory and Immune Reactions", Endothelial Cell Biology, pp. 335-347 (1988).	
	C18	N. Damle et al., "Distinct Regulatory Effects of IL-4 and TNF-alpha during CD3-Dependent and CD3-Independent Initiation of Human T-Cell Activation", Lymph Res., Vol. 8, No. 2, pp. 85-97, (1989).	
	C19	M. Eck et al., "The Structure of Tumor Necrosis Factor-alpha at 2.6A Resolution, Implications for Receptor Binding", J. Biological Chemistry, Vol. 264, No. 29, pp. 17595-17605 (1989).	
	C20	M. Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-beta) at 1.9-A Resolution", J. Biological Chemistry, Vol. 267, No. 4, pp. 2119-2122, (1992).	
	C21	T. Farrar et al., "Emerging Cytokine Family", Nature, Vol. 358, p. 26, (1992).	
	C22	G. Fuh et al., "Rational Design of Potent Antagonists to the Human Growth Hormone Receptor", Science, Vol. 256, pp. 1677-1680, (1992).	

Examiner  
Signature


Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-88)

Approved for use through 10/31/89. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1448B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/040,281
				Filing Date	11/07/2001
				First Named Inventor	Browning, Jeffrey
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	4	of	8	Attorney Docket Number	B129USCP2DV2CO

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C23	D. Goeddel et al., "Tumor Necrosis Factors: Gene Structure and Biological Activities", Cold Spring Harbor Symposia on Quant. Biol., pp. 597-609, (1986).	
	C24	G.A. Granger et al., "Lymphocyte In Vitro Cytotoxicity: Mechanisms of Immune and Non-Immune Small Lymphocyte Mediated Target L Cell Destruction", Journ. of Immun., 101, No. 1, pp. 111-120, (1968).	
	C25	P. Gray, "Molecular Characterization of Human Lymphotoxin", Lymphokines, Vol. 13, pp. 199-208, (1987).	
	C26	P. Gray et al., "Cloning and Expression of cDNA for Human Lymphotoxin. A Lymphokine with Tumor Necrosis Activity", Nature, 312, pp. 721-724, (1984).	
	C27	L. Green et al., "Cytotoxic Lymphokines Produced by Cloned Human Cytotoxic T Lymphocytes", J. of Immun., 135, No. 6, pp. 4034-4043, (1985).	
	C28	L. Green et al., "Rapid Colorimetric Assay for Cell Viability: Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines", J. of Immun. Meth., 70, pp. 257-268, (1984).	
	C29	J. Hiscrodt et al., "Identification of Membrane-Associated Lymphotoxin (LT) on Mitogen-Activated Human Lymphocytes Using Heterologous Anti-LT Antisera in Vitro", Cell. Immun., 34, pp. 326-339, (1977).	
	C30	N. Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen FAS can Mediate Apoptosis", Cell, Vol. 66, pp. 233-243, (1991).	
	C31	E. Jones et al., "Structure of Tumor Necrosis Factor", Nature, 338, pp. 225-228, (1989).	
	C32	A. Kasid et al., "Human Gene Transfer: Characterization of Human Tumor-Infiltrating Lymphocytes as Vehicles for Retroviral-Mediated Gene Transfer in Man", Proc. Natl. Acad. Sci. USA, 87, pp. 473-477, (1990).	
	C33	M. Kinkhabwala et al., "A Novel Addition to the T Cell Repertory", J. Exp. Med., Vol. 171, pp. 941-946, (1990).	


Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐PTO/8B/08B (10-86)  
Approved for use through 10/31/89, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/040,281
				Filing Date	11/07/2001
				First Named Inventor	Browning, Jeffrey
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	5	of	8	Attorney Docket Number	B129USCP2DV2CO


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
	C34	M. Kriegler et al., "A Novel Form of TNF/Cachectin is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF", Cell, Vol. 53, pp. 45-53, (1988).	
	C35	Liang et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin", Biochem. Biophys. Res. Comm., Vol. 137, No. 2, pp. 847-854, (1986).	
	C36	C. Liu et al., "Identification, Isolation, and Characterization of a Novel Cytotoxin in Murine Cytolytic Lymphocytes", Cell, Vol. 51, pp. 393-403, (1987).	
	C37	C. Liu et al., "Identification and Characterization of a Membrane-Bound Cytotoxin of Murine Cytolytic Lymphocytes that is Related to Tumor Necrosis Factor/Cachectin", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3286-3290, (1989).	
	C38	B. Luetig et al., "Evidence for the Existence of Two Forms of Membrane Tumor Necrosis Factor: An Integral Protein and a Molecule Attached to its Receptor", J. Immun., 143, pp. 4034-4038, (1989).	
	C39	S. Mallett et al., "A New Superfamily of Cell Surface Proteins Related to the Nerve Growth Factor Receptor", Immunology Today, Vol. 12, No. 7, pp. 220-223, (1991).	
	C40	L.J. Old, "Tumor Necrosis Factor (TNF)", Science, Vol. 230, pp. 630-632, (1985).	
	C41	N. Paul et al., "Lymphotoxin", Ann. Rev. Immunol., 6, pp. 407-438, (1988).	
	C42	N. Paul et al., "Lymphotoxin Activation by Human T-Cell Leukemia Virus Type I-Infected Cell Lines: Role NF-kB", J. Virol., Vol. 64, No. 11, pp. 5412-5419, (1990).	
	C43	D. Pennica et al., "Human Tumor Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin", Nature, Vol. 312, pp. 724-729, (1984).	
	C44	A. Peterson et al., "Monoclonal Antibody and Ligand Binding Sites of the T Cell Erythrocyte Receptor (CD2)", Nature, Vol. 329, pp. 842-846, (1987).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐PTO/SB/08B (10-88)  
Approved for use through 10/31/88. OMB 0851-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
		Application Number	10/040,281
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	11/07/2001
		First Named Inventor	Browning, Jeffrey
		Group Art Unit	TBD
		Examiner Name	TBD
		Attorney Docket Number	B129USCP2DV2CO
Sheet	6	of	8


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C45	P. Pociot et al., "A Tumor Necrosis Factor beta Gene Polymorphism in Relation to Monokine Secretion and Insulin-Dependent Diabetes Mellitus", Scand. J. Immunol., 33, pp. 37-49, (1991).	
	C46	G. Ranges et al., "Tumor Necrosis Factor-alpha as a Proliferative Signal for an IL-2 Dependent T Cell Line: Strict Species Specificity of Action", J. of Immun., Vol. 142, pp. 1203-1208, (1989).	
	C47	G. Ranges et al., "Tumor Necrosis Factor alpha/Cachectin is a Growth Factor for Thymocytes", J. Exp. Med., Vol. 167, pp. 1472-1478, (1988).	
	C48	G.D. Roodman et al., "Tumor Necrosis Factor-alpha and Hematopoietic Progenitors: Effects of Tumor Necrosis Factor on the Growth of Erythroid Progenitors CFU-E and BFU-E and Hematopoietic Cell Lines K562, HL60, and HBL Cells", Exp. Hematology, 15, pp. 928-935, (1987).	
	C49	S. Rosenberg et al., "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma: A Preliminary Report", New Eng. Jour. of Med., Vol. 319, pp. 1676-1680, (1988).	
	C50	N. Ruddle, "Lymphotoxin Redux", Immun. Today, 6, pp. 156-159, (1985).	
	C51	N. Ruddle et al., "Cytotoxicity Mediated by Soluble Antigen and Lymphocytes in Delayed Hypersensitivity", J. Exp. Med., 128, pp. 1237-1279, (1968).	
	C52	N. Ruddle et al., "The Role of Lymphotoxin in Inflammation", Prog. Allergy, Vol. 40, pp. 162-182, (1988).	
	C53	K. Sastry et al., "HIV-1 tat Gene Induces Tumor Necrosis Factor-beta (Lymphotoxin) in a Human beta-Lymphoblastoid Cell Line", J. Biol. Chem., Vol. 265, No. 3, pp. 20091-20093, (1990).	
	C54	T. Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", Cell, Vol. 61, pp. 361-370, (1990).	
	C55	P. Scheurich et al., "Immunoregulatory Activity of Recombinant Human Tumor Necrosis Factor (TNF)-alpha: Induction of TNF Receptors on Human T Cells and TNF-alpha-Mediated Enhancement of T Cell Responses", J. Immun., Vol. 138, pp. 1786-1790 (1987).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-86)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **7** of **8****Complete if Known**

Application Number	10/040,281
Filing Date	11/07/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	B129USCP2DV2CO

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T*
	C56	M. Shalaby et al., "The Involvement of Human Tumor Necrosis Factors-alpha and -beta in the Mixed Lymphocyte Reaction", J. Immun., Vol. 141, pp. 499-503, (1988).	
	C57	M. Sigel et al., "Production of Antibodies by Inoculation into Lymph Nodes", Meth. in Enz., Vol. 93, pp. 3-12 (1983).	
	C58	C. Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", Science, 248, pp. 1019-1023, (1990).	
	C59	D. Spriggs et al., "Tumor Necrosis Factor Expression in Human Epithelial Tumor Cell Lines", J. Clin. Invest., Vol. 81, pp. 455-460, (1988).	
	C60	J. Tavernier et al., "Conserved Residues of Tumor Necrosis Factor and Lymphotoxin Constitute the Framework of the Trimeric Structure", Fed. Eur. Biochem. Soc. Letters, Vol. 257, No. 2, pp. 315-318, (1989).	
	C61	H. Thomas et al., "Biological Approaches to Cancer Therapy", J. Int. Med. Res., 17, pp. 191-204 (1989).	
	C62	M. Turner et al., Human T Cells from Autoimmune and Normal Individuals can Produce Tumor Necrosis Factor", Eur. J. Immun., 17, pp. 1807-1814 (1987).	
	C63	E. Tschachler et al., "Human Retrovirology: Constitutive Expression of Lymphotoxin (Tumor Necrosis Factor beta) in HTLV-I-Infected Cell Lines", Raven Press, pp. 105-113, (1990).	
	C64	R. Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis", Nature, 356, pp. 314-317, (1992).	
	C65	C. Ware et al., "Mechanisms of Lymphocyte-Mediated Cytotoxicity", J. Immun., Vol. 126, pp. 1927-1933, (1981).	
	C66	C. Ware et al., "Human T Cell Hybridomas Producing Cytotoxic Lymphokines: Induction of Lymphotoxin Release and Killer Cell Activity by Anti-CD3 Monoclonal Antibody or Lectins and Phorbol Ester", Lymphokine Res., Vol. 5, No. 4, pp. 313-324, (1986).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-00)  
 Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/040,281
				Filing Date	11/07/2001
				First Named Inventor	Browning, Jeffrey
				Group Art Unk	TBD
				Examiner Name	TBD
Sheet	8	of	8	Attorney Docket Number	B129USCP2DV2CO

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C67	C. Ware et al., "Regulation of the CTL Lytic Pathway by Tumor Necrosis Factor", Cellular Immunity and the Immunotherapy of Cancer", UCLA Symposia on Molecular and Cell Biology M.T. Lotze and O.J. Finn, Eds., Vol. 135, pp. 121-128, (Wiley-Liss Inc. New York) 1990.	
	C68	C. Ware et al., "Expressions of Surface Lymphotoxin and Tumor Necrosis Factor on Activated T. B, and Natural Killer Cells", J. Immunol., Vol. 149, No. 12, pp. 3881-3888, (1992).	
	C69	L. Wysocki, U. Sato, "'Panning" for Lymphocytes: A Method for Cell Selection", Proc. Natl. Acad. Sci. USA, Vol. 75, pp. 2844-2848, (1978).	
	C70	H. Yamanaka et al., "Identity of Human B-Cell Line Cytotoxic Lymphokine with Tumor Necrosis Factor Type beta", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 1343-1347, (1989)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**